(UroToday.com) The 2024 SUO annual meeting included a session on non muscle invasive bladder cancer, featuring a presentation by Dr. Ashish Kamat discussing BCG unresponsive cancer in 2024.

SUO annual meeting included a session on non muscle invasive bladder cancer (NMIBC), featuring a presentation by Dr. Sima Porten discussing the heterogeneity of intermediate risk NMIBC. Based on the ...

Bladder cancer ranks as the 10th most commonly diagnosed cancer globally, affecting both men and women. Approximately 75% of patients are initially diagnosed with non-muscle invasive bladder cancer ...

UroGen Pharma has reported the outcomes from a long-term follow-up study of JELMYTO for pyelocalyceal solution for treating ...

Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in patients with FGFR-altered high- and intermediate-risk non–muscle invasive ...

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive ...

Details on the late-breaking abstract and posters are as follows: Topline Results from BOND-003: A Phase-3 Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk ...

Although the use of intravesical immunotherapy for reducing tumor progression or as maintenance therapy is controversial, bacillus Calmette–Guérin has demonstrated significant benefit for tumor ...

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to ...

The ADVANCED-2 trial is assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-unresponsive (n≈100) and BCG-Naïve (n=27).

CG Oncology (CGON) announced the publication in Nature Medicine of Phase 1b investigator-sponsored study results evaluating intravesical cretostimogene grenadenorepvec in combination with Bristol ...

Additionally, at 1 year, the recurrence-free survival rate was 70.4%. The authors also observed, “Although T cell infiltration was broadly induced following intravesical oncolytic virotherapy, the ...